Data Sheet (Cat.No.T40249)

TargetMol®
YOUR TARGET MOLECULES

PCC0208017

Chemical Properties

CAS No. : 2623158-64-3

Formula: C19H20F3N7

Molecular Weight: 403.4

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

Description	PCC0208017 is an inhibitor of MARK3 and MARK4 with IC50s of 1.8 and 2.01 nM. PCC0208017 disrupts microtubule dynamics and displays potent antitumor activity.
Targets(IC50)	Apoptosis
In vitro	PCC0208017 has much lower inhibitory activity against MARK1 and MARK2, with IC50s of 31.4 and 33.7 nM, respectively. PCC0208017 (1-5 μM) decreases the phosphorylation of Tau. PCC0208017 (3-21 μM) suppresses the proliferation of glioma cells[1].
In vivo	In C57BL/6 mice bearing murine glioma GL261 xenograft tumor, PCC0208017 (50 and 100 mg/kg; oral) dose-dependently inhibits the growth of xenograft tumors derived with inhibition rates of 56.15% and 70.32%, respectively. PCC0208017 (50 mg/kg; oral) exhibits Cmax and Tmax of 1.36 μg/mL and 0.833 h in plasma and 0.14 μg/mL and 0.833 h in brain[1]. Co-treatment of PCC0208017 (50 mg/kg) significantly enhances the anti-tumor activity of Temozolomide (100 mg/kg) with inhibition rates from 34.15% to 83.5%[1].

Solubility Information

Solubility	DMSO: 112.5 mg/mL (278.9 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.4789 mL	12.3946 mL	24.7893 mL
5 mM	0.4958 mL	2.4789 mL	4.9579 mL
10 mM	0.2479 mL	1.2395 mL	2.4789 mL
50 mM	0.0496 mL	0.2479 mL	0.4958 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Fangfang Li, et al. PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression in vitro and in vivo. Acta Pharm Sin B.2020 Feb;10(2):289-300.

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481